Comment Oral GLP-1 receptor agonists: competition for efficacy and tolerability Michael A Nauck,Michael Horowitz +++... +

Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial Prof Chloe Orkin, MDa c.m.orkin@qmul.ac.uk ∙ Peter J Ruane, MDb ∙ Malcolm Hedgcock, MDc ∙ Cyril Gaultier, MDd ∙ Prof Marcelo H Losso, MDe,f ∙ Benoit Trottier, MDg ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00307-7/fulltext?dgcid=hubspot_email_conferencealerts_croi26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-91M5bhF5qzAqzlaqFCPWtsfvPvo3OXkzrQ2ujxeTpEJuZ2HYDhk6ftmaZC-GslqKwleAYDNVBsGTZMVWdrxkSE5IwRww&_hsmi=405519679&utm_content=405519679&utm_source=hs_email Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial Prof Jürgen K Rockstroh, MDa ∙ Sheetal Kassim, MDb ∙ Roger Paredes, PhDc,d,e ∙ Christopher Bettacchi, MDf ∙ Gary Sinclair, MDg ∙ Anchalee Avihingsanon, MDh ∙ et al. https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00033-0/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_croi26&_hsenc=p2ANqtz--VPAxr8fcBTG4bnoCELgBXznyfyCBCq2XDdf7bx-_EVkKwdFTkxI7QCvODcHj9yfqsLIXg8U4P1B0IAyF8rPPfHoXAOw&_hsmi=405519679&utm_content=405519679&utm_source=hs_email Comment Oral GLP-1 receptor agonists: competition for efficacy and tolerability Michael A Nauck,Michael Horowitz https://www.thelancet.com/journals/lancet/onlinefirst Managing complex antiretroviral regimens Michael S Saag https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00364-8/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_croi26&_hsenc=p2ANqtz-9S-JImB9lO5qo_6WfA1WG_M_aqHSHIh9NNEpfQN9qN1_GnoE665ALe-TbY5fNM5Dr-fDbfMLL-j1TNzHdmBfFvq3uuHg&_hsmi=405519679&utm_content=405519679&utm_source=hs_email